FDA Accepts Supplement Application for SKYRIZI (Risankizumab)
The FDA has accepted a supplemental application for SKYRIZI, indicating ongoing development and potential label expansion.
Therapeutic Area
Therapeutic area intelligence for IL-23 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.